Lu Xianping works in a lab at Shenzhen Chipscreen Biosciences Ltd. in Shenzhen, south China's Guangdong Province, May 20, 2015. Lu Xianping, together with other four returned overseas scientists, spent 14 years to develop Chidamide, the world's first oral HDAC inhibitor, which was given regulatory approval in January. (Xinhua/Mao Siqian)

Lu Xianping uses a microscope at Shenzhen Chipscreen Biosciences Ltd. in Shenzhen, south China's Guangdong Province, May 20, 2015. Lu Xianping, together with other four returned overseas scientists, spent 14 years to develop Chidamide, the world's first oral HDAC inhibitor, which was given regulatory approval in January. (Xinhua/Mao Siqian)

Lu Xianping works at his company at Shenzhen Chipscreen Biosciences Ltd. in Shenzhen, south China's Guangdong Province, May 20, 2015. Lu Xianping, together with other four returned overseas scientists, spent 14 years to develop Chidamide, the world's first oral HDAC inhibitor, which was given regulatory approval in January. (Xinhua/Mao Siqian)

Lu Xianping works in a lab at Shenzhen Chipscreen Biosciences Ltd. in Shenzhen, south China's Guangdong Province, May 20, 2015. Lu Xianping, together with other four returned overseas scientists, spent 14 years to develop Chidamide, the world's first oral HDAC inhibitor, which was given regulatory approval in January. (Xinhua/Mao Siqian)

Lu Xianping checks research data at Shenzhen Chipscreen Biosciences Ltd. in Shenzhen, south China's Guangdong Province, May 20, 2015. Lu Xianping, together with other four returned overseas scientists, spent 14 years to develop Chidamide, the world's first oral HDAC inhibitor, which was given regulatory approval in January. (Xinhua/Mao Siqian)

Lu Xianping looks at the photo of his sons at Shenzhen Chipscreen Biosciences Ltd. in Shenzhen, south China's Guangdong Province, May 20, 2015. Lu Xianping, together with other four returned overseas scientists, spent 14 years to develop Chidamide, the world's first oral HDAC inhibitor, which was given regulatory approval in January. (Xinhua/Mao Siqian)

Photo taken on May 22, 2015 shows a box of Chidamide in Shenzhen, south China's Guangdong Province. Chidamide is the world's first oral HDAC inhibitor developed by Shenzhen Chipscreen Biosciences Ltd., which was given regulatory approval in January. Lu Xianping, together with other four returned overseas scientists, spent 14 years to develop Chidamide. (Xinhua/Mao Siqian)